β-defensin 9 inhibitors are a class of chemical compounds that specifically interact with and inhibit the function of β-defensin 9, a small cationic peptide belonging to the defensin family. Defensins are a group of host defense peptides that play a crucial role in the innate immune system of many organisms, including humans. β-defensin 9, in particular, is characterized by its broad-spectrum antimicrobial activity and its role in modulating immune responses. The inhibition of β-defensin 9 typically involves binding to the peptide or interacting with its active sites to prevent it from exerting its biological functions. This inhibition can affect processes like cell signaling, membrane interaction, or peptide binding, depending on the specific mode of action of the inhibitor. Chemical entities identified as β-defensin 9 inhibitors often possess unique structural features that allow for a high degree of specificity and binding affinity, which are critical for effectively modulating the biological pathways in which β-defensin 9 is involved.
Research into β-defensin 9 inhibitors often focuses on understanding the structural and biochemical characteristics that govern their interaction with β-defensin 9. This includes studies on the molecular dynamics of the inhibitor-peptide complex, the thermodynamics of binding, and the conformational changes induced upon inhibitor binding. Such inhibitors are valuable tools in the study of β-defensin 9's function in cellular processes and its interactions with microbial membranes or immune cells. Additionally, these inhibitors can be useful in exploring the broader role of defensins in immunity and inflammation. Structural studies often employ techniques such as X-ray crystallography, NMR spectroscopy, and computational modeling to elucidate the precise nature of the binding interaction between the inhibitors and β-defensin 9. The development and characterization of β-defensin 9 inhibitors provide insight into the fundamental aspects of peptide function and regulation, contributing to a deeper understanding of immune system modulation at the molecular level.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, inhibiting the PI3K/AKT pathway, influences β-defensin 9 by disrupting the downstream signaling, altering its expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, inhibiting mTOR, indirectly influences β-defensin 9 by modulating mTOR-related pathways, leading to alterations in peptide expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 modulates NF-κB, impacting β-defensin 9 regulation by influencing NF-κB-mediated transcriptional control of the gene. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MAPK pathway inhibitor, indirectly affects β-defensin 9 by modulating the MAPK signaling cascade, leading to altered gene expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, inhibiting the PI3K/AKT pathway, indirectly influences β-defensin 9 expression by disrupting the downstream signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly influences β-defensin 9 by altering the cellular environment through p38 MAPK pathway inhibition. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
A selective NF-κB inhibitor, indirectly modulates β-defensin 9 by impacting NF-κB-mediated transcriptional control of the gene. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
MK-2206, inhibiting the PI3K/AKT pathway, indirectly influences β-defensin 9 by disrupting the downstream signaling cascade, altering its expression. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $66.00 $273.00 | 3 | |
LY303511, a PI3K/AKT pathway inhibitor, indirectly influences β-defensin 9 by disrupting the downstream signaling cascade, leading to altered gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125, a JNK inhibitor, indirectly influences β-defensin 9 by modulating the JNK signaling cascade, altering the cellular environment and gene expression. |